Is Compounded Semaglutide Still Legal?
The shortage ended in February 2025 and the grace periods closed that spring. What the FDA position actually permits now, and the rule almost nobody quotes.
For about two years, compounded semaglutide occupied a legal space that most people using it never had explained to them. That space has closed, and the closure happened on specific dates rather than gradually.
This is not a question about whether compounded semaglutide works. It is a question about which legal mechanism permitted it, and whether that mechanism is still there.
Why it was ever permitted
United States law lets a compounder work with a bulk active ingredient in circumstances an ordinary pharmacy could not. One of those circumstances is a drug being on the FDA drug shortage list.
Semaglutide went onto that list during the demand surge, and that listing — not a judgement about compounded versions being equivalent — is what opened the route. The permission was always contingent. It was attached to the shortage, and a shortage is by definition temporary.
The dates the position changed
| Date | What happened |
|---|---|
| 21 February 2025 | FDA declared the injectable semaglutide shortage resolved |
| 5 March 2025 | Court declined to block the equivalent tirzepatide decision |
| 19 March 2025 | Tirzepatide: enforcement discretion ended for outsourcing facilities (503B) |
| 22 April 2025 | Semaglutide: enforcement discretion ended for state-licensed pharmacies (503A) |
| 24 April 2025 | Court declined to block the semaglutide decision |
| 22 May 2025 | Semaglutide: enforcement discretion ended for outsourcing facilities (503B) |
| 1 April 2026 | FDA restated the conditions compounders must meet |
The two legal categories in that table are worth separating, because they are routinely merged. 503A is a state-licensed pharmacy compounding for an individual patient against a prescription. 503B is an outsourcing facility producing at larger scale without patient-specific prescriptions. They operate under different conditions and their deadlines fell a month apart.
As things stand, neither tirzepatide nor semaglutide appears on the 503B bulks list or on the FDA drug shortage list.
What actually remains
Here is where most coverage stops too early, and gets the answer wrong in both directions.
The 503A pathway did not disappear when the shortage resolved. Patient-specific compounding by a state-licensed pharmacy rests on a different part of the statute, which does not depend on shortage status. What constrains it instead is the rule against compounding a product that is essentially a copy of a commercially available drug.
The FDA treats a compounded product as essentially a copy when it has the same active ingredient as a marketed drug, in the same, similar or easily substitutable strength, and can be used by the same route of administration. Semaglutide injection is commercially available. A compounded semaglutide injection is therefore, on its face, a copy.
The exception is documented clinical need: a prescriber determining and recording that a compounded product contains a change producing a significant difference for an identified individual patient. That is a real route, and it is narrower than the marketing around it suggests.
The B12 point
Combining semaglutide with something else does not automatically escape the copy rule. The FDA has said it may treat a semaglutide-plus-vitamin-B12 product as essentially a copy where the route of administration matches and the amounts of each ingredient sit within 10% of the corresponding commercially available strengths.
The rule almost nobody quotes
There is one more provision, and it explains a great deal about what remains available in practice. The FDA has stated it does not intend to act against a compounder for compounding a product that is essentially a copy regularly or in inordinate amounts if that compounder fills four or fewer prescriptions of that product in a calendar month.
That is an enforcement-discretion threshold, not a licence. But it is the reason a small pharmacy and a large telehealth operation are not in the same position, and it is why “is it legal” has no single answer that covers both.
None of the above is legal advice, and none of it is a view on whether a compounded product is equivalent to a branded one. Where a specific prescription sits is a question for the prescriber and the pharmacy, under the law of the place they operate in. The dates and conditions here come from the FDA’s own statements, which are linked in the sources.
What this means outside the United States
The compounding framework above is US law and does not transfer. The EU has no equivalent of the 503A bulks mechanism, and semaglutide is authorised centrally through the European Medicines Agency.
The practical consequence in Europe is narrower rather than wider: a product that is not the authorised one is not made lawful by an American shortage list. That question is its own topic, and the answer runs through EU medicines law rather than through compounding rules.
The practical part
If the source of a vial changes, the arithmetic usually changes with it.
A branded pen delivers a fixed amount per click and hides the concentration entirely. A compounded vial does not: it has a concentration, and what appears on a syringe depends on it. Those are two different measurement problems, and moving between them is where errors cluster — the reconstitution arithmetic is the same as for any vial, and the calculator will convert a quantity and a volume into syringe units.
What is worth writing down at that moment is the concentration and the date, not the click count. A pen’s numbers do not describe a vial, and a record that mixes the two silently stops meaning anything.
Frequently asked questions
Is compounded semaglutide still legal in 2026?
The blanket route is gone. Compounding that depended on semaglutide being on the FDA drug shortage list ended for state-licensed pharmacies on 22 April 2025 and for outsourcing facilities on 22 May 2025. A narrow patient-specific route under section 503A still exists, but it is constrained by the rule against compounding what is essentially a copy of a commercially available drug.
What does "essentially a copy" mean?
The FDA treats a compounded product as essentially a copy when it has the same active ingredient as a commercially available drug, in the same, similar or easily substitutable strength, usable by the same route of administration. A prescriber can document that a specific patient needs a change producing a significant difference, which is the exception the remaining route runs through.
Does adding vitamin B12 make it a different product?
Not automatically. The FDA has said it may consider a compounded product combining semaglutide with another ingredient such as vitamin B12 to be essentially a copy, where the route of administration is the same and the amounts of each are within 10% of the strengths of the corresponding commercially available products.
Is tirzepatide in the same position?
Broadly yes, and it moved first. Enforcement discretion for state-licensed pharmacies ended after the court ruling of 5 March 2025, and for outsourcing facilities on 19 March 2025. Neither tirzepatide nor semaglutide currently appears on the 503B bulks list or on the FDA drug shortage list.